If you have been reading about modified GRF(1-29) and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Primary target | GHRH receptor | G-protein-coupled receptor on pituitary somatotrophs |
| Half-life, long-acting form | Several days | Extended by covalent albumin binding |
| Half-life, short form | About 30 minutes | Cleared rapidly by peptidases and kidneys |
| Route in studies | Subcutaneous injection | Used in the published human trials |
| Main measured effect | Rise in GH and IGF-1 | Surrogate markers rather than clinical endpoints |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
epistasis The collective action of multiple genes interacting during gene expression. A form of gene action, epistasis can be either additive or multiplicative in its effects on specific phenotypic traits.
The α-helix is the most abundant type of secondary structure in proteins. The α-helix has 3.6 amino acids per turn with an H-bond formed between every fourth residue; the average length is 10 amino acids (3 turns) or 10 Å but varies from 5 to 40 (1.5 to 11 turns). The alignment of the H-bonds creates a dipole moment for the helix with a resulting partial positive charge at the amino end of the helix. Because this region has free NH2 groups, it will interact with negatively charged groups such as phosphates. The most common location of α-helices is at the surface of protein cores, where they provide an interface with the aqueous environment. The inner-facing side of the helix tends to have hydrophobic amino acids and the outer-facing side hydrophilic amino acids. Thus, every third of four amino acids along the chain will tend to be hydrophobic, a pattern that can be quite readily detected. In the leucine zipper motif, a repeating pattern of leucines on the facing sides of two adjacent helices is highly predictive of the motif. A helical-wheel plot can be used to show this repeated pattern. Other α-helices buried in the protein core or in cellular membranes have a higher and more regular distribution of hydrophobic amino acids, and are highly predictive of such structures. Helices exposed on the surface have a lower proportion of hydrophobic amino acids. Amino acid content can be predictive of an α-helical region.
=== Non-profit research === But not all those who engage in cyberwarfare do so for financial or ideological reasons. There are institutes and companies like the University of Cincinnati or the Kaspersky Security Lab which engage in cyberwarfare so as to better understand the field through actions like the researching and publishing of new security threats.
=== Ka–Ke === Henrik Kacser FRSE (1918–1995). British geneticist and biochemist at Edinburgh, founder of metabolic control analysis. Emil T. Kaiser (1938–1988). Hungarian-born American protein chemist at the University of Chicago, known for his work on enzyme modification. Member Natl. Acad. Sci. USA. Herman Kalckar (1908–1991). Danish biochemist at the New York Public Health Research Institute, who worked on cellular respiration, nucleotide metabolism and galactose metabolism. Member Natl. Acad. Sci. USA Nathan O. Kaplan (1917–1986) Enzymologist at UC San Diego, founding editor of Methods in Enzymology. Member Natl. Acad. Sci. USA Sir Bernard Katz FRS (1911–2003). German-British neuroscientist and biophysicist at University College London. Nobel Prize in Physiology or Medicine (1970) for work on nerve biochemistry and the pineal gland. Stuart Alan Kauffman (b. 1939). American theoretical biologist, expert on complex systems, now at the University of Pennsylvania. Fellow of the Royal Society of Canada. Douglas Kell (b. 1953). British biochemist at the University of Manchester, known for research on functional genomics, metabolomics and the yeast genome. John Kendrew FRS (1917–1997). British x-ray crystallographer at the European Molecular Biology Laboratory, Heidelberg, known for determining the crystal structure of myoglobin. Nobel Prize in Chemistry (1962). Sir Ernest Kennaway FRS (1881–1958), British pathologist at the Institute of Cancer Research, London, who carried out early work on carcinogenic effects of hydrocarbons. Eugene P.
Sources: en.wikipedia.org
In the late 19th century anorexia nervosa became widely accepted by the medical profession as a recognized condition, with mentions in the medical literature notably arising from the Salpêtrière clinic in Paris by physicians such as Jean-Martin Charcot. Awareness of the condition was largely limited to the medical profession until the latter part of the 20th century, when German-American psychoanalyst Hilde Bruch published The Golden Cage: the Enigma of Anorexia Nervosa in 1978. Despite major advances in neuroscience, Bruch's theories tend to dominate popular thinking. A further important event was the death of the popular singer and drummer Karen Carpenter in 1983, which prompted widespread ongoing media coverage of eating disorders.
== Career == He joined the Ethiopian Ministry of Foreign Affairs in 1978, serving as Ethiopia/EEC Relations Desk Officer. In 1983 he was mandated to the Diplomatic Mission in Brussels, with the title of economist. Berhanu participated in negotiations leading to the 1981 and 1985 extensions of the Lomé Convention – an agreement concerning international aid and trade between the African, Caribbean and Pacific countries and the European Union – as well as participating in the committees that managed this convention. In 1992 Berhanu returned to Addis Ababa to lead the Western European Division at the Ministry at the rank of Counselor, before taking on the role of Acting Director General for International Organisation and Economic Cooperation in 1993. Later that year he was promoted to Director General, and it was in this role that he represented Ethiopia at all of the Organisation of African Unity Council and Summit conferences held between 1992 and 2000, as well as the Economic Commission for Africa Ministerial Conferences held in this period, chaired the Economic and Social Council meeting of the African Economic Community in June 1998, and served as deputy leader of the Ethiopian delegation to the United Nations from 1993 to 2000. On 7 December 2000, he was appointed the Ethiopian ambassador to Russia. In February 2002, he was appointed Ambassador of Ethiopia to Sweden and concurrently Norway, Denmark, Finland and Iceland. In March 2006 he was appointed as Ambassador of Ethiopia to the United Kingdom, a position he held during 10 years. In 2016, H.E.
Cdc25 phosphatase catalytic domain non-catalytic domains of eukaryotic dual-specificity MAPK-phosphatases non-catalytic domains of yeast PTP-type MAPK-phosphatases non-catalytic domains of yeast Ubp4, Ubp5, Ubp7 non-catalytic domains of mammalian Ubp-Y Drosophila heat shock protein HSP-67BB several bacterial cold-shock and phage shock proteins plant senescence associated proteins catalytic and non-catalytic domains of rhodanese Rhodanese has an internal duplication. This domain is found as a single copy in other proteins, including phosphatases and ubiquitin C-terminal hydrolases. While cyanide is the most well-characterized sulfur acceptor from rhodanese, biological thiols such as glutathione are capable of acting as acceptors to form free low-molecular weight hydropersulfides such as glutathione hydropersulfide.
=== Evolutionary variation of homologous RNA sequences reveals folding patterns === Additional tRNA molecules were purified and sequenced. The first comparative sequence analysis was done and revealed that the sequences varied through evolution in such a way that all of the tRNAs could fold into very similar secondary structures (two-dimensional structures) and had identical sequences at numerous positions (e.g. CCA at the 3′ end). The radial four-arm structure of tRNA molecules is termed the "cloverleaf structure", and results from the evolution of sequences with common ancestry and common biological function. Since the discovery of the tRNA cloverleaf, comparative analysis of numerous other homologous RNA molecules has led to the identification of common sequences and folding patterns.
=== Cannabis === In March 2021, Talarico introduced House Bill 4089 to legalize adult cannabis use and provide for the expungement of past convictions. During the 2025 legislative session, he opposed Senate Bill 3, which sought to ban most hemp-derived THC products, arguing that the ban would undermine the state industry and shift consumers toward unregulated markets.
Sources: en.wikipedia.org
==== Protein purification and separation ==== By immobilizing proteins to polymer nanoparticles or polymer/inorganic hybrid nanoparticles (such as polymer-stabilized iron oxide nanoparticles), proteins or their affinity ligands can be separated from complex solutions by applying magnetic fields or centrifugation. Lipase attached to iron oxide nanoparticles maintained 85% biological activity after 30 reaction and separation cycles. As the appropriate target is combined with magnetic nanoparticles, the selected target can be magnetically separated directly from natural biological fluids, which offers a fast, gentle, extensible, and easy to automate separation technique. The simplicity of magnetic separation has been applied in a number of disciplines, including mineral processing wastewater treatment, molecular biology, cell sorting, and clinical diagnostics.
In 2010 protein-energy malnutrition resulted in 600,000 deaths down from 883,000 deaths in 1990. Other nutritional deficiencies, which include iodine deficiency and iron deficiency anemia, result in another 84,000 deaths. In 2010 malnutrition caused about 1.5 million deaths in women and children. According to the World Health Organization, malnutrition is the biggest contributor to child mortality, present in half of all cases. Six million children die of hunger every year. Underweight births and intrauterine growth restrictions cause 2.2 million child deaths a year. Poor or non-existent breastfeeding causes another 1.4 million. Other deficiencies, such as lack of vitamin A or zinc, for example, account for 1 million. Malnutrition in the first two years is irreversible. Malnourished children grow up with worse health and lower education achievement. Their own children tend to be smaller. Malnutrition was previously seen as something that exacerbates the problems of diseases such as measles, pneumonia and diarrhea, but malnutrition actually causes diseases, and can be fatal in its own right.
=== EC 1.5.1 With NAD+ or NADP+ as acceptor === EC 1.5.1.1: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NAD(P)H) EC 1.5.1.2: pyrroline-5-carboxylate reductase EC 1.5.1.3: dihydrofolate reductase EC 1.5.1.4: Now included with EC 1.5.1.3 dihydrofolate reductase EC 1.5.1.5: methylenetetrahydrofolate dehydrogenase (NADP+) EC 1.5.1.6: formyltetrahydrofolate dehydrogenase EC 1.5.1.7: saccharopine dehydrogenase (NAD+, L-lysine-forming) EC 1.5.1.8: saccharopine dehydrogenase (NADP+, L-lysine-forming) EC 1.5.1.9: saccharopine dehydrogenase (NAD+, L-glutamate-forming) EC 1.5.1.10: saccharopine dehydrogenase (NADP+, L-glutamate-forming) EC 1.5.1.11: D-octopine dehydrogenase EC 1.5.1.12: Now EC 1.2.1.88, L-glutamate γ-semialdehyde dehydrogenase EC 1.5.1.13: Now EC 1.17.1.5, nicotinate dehydrogenase EC 1.5.1.14: Now included with EC 1.5.1.21 Δ1-piperideine-2-carboxylate reductase EC 1.5.1.15: methylenetetrahydrofolate dehydrogenase (NAD+) EC 1.5.1.16: D-lysopine dehydrogenase EC 1.5.1.17: alanopine dehydrogenase EC 1.5.1.18: ephedrine dehydrogenase EC 1.5.1.19: D-nopaline dehydrogenase EC 1.5.1.20: methylenetetrahydrofolate reductase (NAD(P)H) EC 1.5.1.21: 1-piperideine-2-carboxylate/1-pyrroline-2-carboxylate reductase (NADPH) EC 1.5.1.22: strombine dehydrogenase EC 1.5.1.23: tauropine dehydrogenase EC 1.5.1.24: N5-(carboxyethyl)ornithine synthase EC 1.5.1.25: thiomorpholine-carboxylate dehydrogenase EC 1.5.1.26: β-alanopine dehydrogenase EC 1.5.1.27: 1,2-dehydroreticulinium reductase (NADPH) EC 1.5.1.28: opine dehydrogenase EC 1.5.1.29: Now covered by EC 1.5.1.38 [FMN reductase (NADPH)], EC 1.5.1.39 [FMN reductase [NAD(P)H])] and EC 1.5.1.41 (riboflavin reductase [NAD(P)H]) EC 1.5.1.30: flavin reductase (NADPH) EC 1.5.1.31: berberine reductase EC 1.5.1.32: vomilenine reductase EC 1.5.1.33: pteridine reductase EC 1.5.1.34: 6,7-dihydropteridine reductase EC 1.5.1.35: identical to EC 1.2.1.19, aminobutyraldehyde dehydrogenase, as the substrates 1-pyrroline and 4-aminobutanal are interconvertible EC 1.5.1.36: flavin reductase (NADH) EC 1.5.1.37: FAD reductase (NADH) EC 1.5.1.38: FMN reductase (NADPH) EC 1.5.1.39: FMN reductase (NAD(P)H) EC 1.5.1.40: 8-hydroxy-5-deazaflavin:NADPH oxidoreductase EC 1.5.1.41: riboflavin reductase (NAD(P)H) EC 1.5.1.42: FMN reductase (NADH) EC 1.5.1.43: carboxynorspermidine synthase EC 1.5.1.44: festuclavine dehydrogenase EC 1.5.1.45: FAD reductase (NAD(P)H) EC 1.5.1.46: agroclavine dehydrogenase EC 1.5.1.47: dihydromethanopterin reductase [NAD(P)+] EC 1.5.1.48: 2-methyl-1-pyrroline reductase EC 1.5.1.49: 1-pyrroline-2-carboxylate reductase [NAD(P)H] EC 1.5.1.50: dihydromonapterin reductase EC 1.5.1.51: N-[(2S)-2-amino-2-carboxyethyl]-L-lutamate dehydrogenase EC 1.5.1.52: staphylopine dehydrogenase EC 1.5.1.53: methylenetetrahydrofolate reductase (NADPH) EC 1.5.1.54: methylenetetrahydrofolate reductase (NADH)
In parallel, he decided to try out for Saturday Night Live again, this time ahead of the show's 1985–86 season being prepared by returning executive producer Lorne Michaels who was looking to hire an all-new cast. Five years removed from his previous SNL audition, twenty-three-year-old Carrey was rejected again, reportedly never even getting the chance to audition his material—'post-nuclear Elvis' hybrid impression and impersonation of Henry Fonda from On Golden Pond—in front of executive producer Michaels due to the show's producers and senior writers Al Franken, Tom Davis, and Jim Downey deciding that Michaels would not like it. Unlike his previous SNL rejection, Carrey now had a bit of a film career to fall back on in addition to his impressionist stand-up act; Once Bitten was released in mid November 1985 and turned out to be a modest box-office hit despite drawing poor reviews. Back on the comedy club circuit with impressions, in fall 1986, Carrey auditioned for SNL's upcoming season, his third attempt at getting on the ensemble sketch comedy show. Finally managing to perform for the show's executive producer Lorne Michaels at a Burbank studio, with returning cast members Dennis Miller, Jon Lovitz, and Nora Dunn also watching the audition, Carrey was rejected again. Among the group of hopefuls auditioning alongside Carrey on this occasion were Dana Carvey and Phil Hartman, both of whom were hired. Sensing that doing only impressions was turning into a career dead-end, Carrey set out to develop a new live comedy act.
Sources: en.wikipedia.org
It binds the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Receptor activation raises cyclic AMP and promotes release of stored growth hormone granules. Because the peptide persists longer than natural releasing hormone, stimulation is prolonged rather than brief.
The drug affinity complex links the peptide to serum albumin through a covalent bond. The conjugate is too large to be filtered quickly by the kidneys and is shielded from enzymatic breakdown. This extends the apparent half-life from roughly minutes to several days.
Long-term safety and any clinical benefit are unestablished. Published human data cover small groups over limited periods and focus on hormone levels rather than health outcomes. Whether prolonged elevation of growth hormone and insulin-like growth factor 1 is beneficial or harmful is an open question.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.